Phosphorus prodrugs of pyrazolo-substituted pyrimidine sgc stimulators
US-2024360164-A1 · Oct 31, 2024 · US
Methods of inhibiting vascular permeability and apoptosis
US9101575B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9101575-B2 |
| Application number | US-89478310-A |
| Country | US |
| Kind code | B2 |
| Filing date | Sep 30, 2010 |
| Priority date | Jun 24, 2003 |
| Publication date | Aug 11, 2015 |
| Grant date | Aug 11, 2015 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Agonists of vascular endothelial sphingosine-1-phosphate receptors are described. Compounds such as FTY720 can be phosphorylated by sphingosine kinase-2 into the phosphorylated forms which serve as sphingosine-1-phosphate receptor agonists. The vascular endothelial sphingosine-1-phosphate receptor agonists are employed in methods of treating a mammal for vascular permeability disorders and unwanted vascular endothelial cell apoptosis, and for the growth of new blood vessels. The sphingosine-1-phosphate receptor agonists can be used for the manufacture of a medicament for treating vascular permeability disorders and unwanted vascular endothelial cell apoptosis, and for the growth of new blood vessels.
First claim
Opening claim text (preview).
What is claimed is: 1. A method of treating Alzheimer's disease, comprising administering to a mammal in need of treatment for Alzheimer's disease a therapeutically effective amount of a compound selected from the group consisting of 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol, 2-amino-3-phosphate-2-[2-(4-octylphenyl)ethyl]propane-1-ol, or pharmaceutically acceptable salts thereof.
Assignees
Inventors
Classifications
Patent family
Related publications grouped by family.
External sources
Next steps
Free tools are coming soon. Tell us what you want to track and we'll notify you.
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9101575B2 cover?
- Agonists of vascular endothelial sphingosine-1-phosphate receptors are described. Compounds such as FTY720 can be phosphorylated by sphingosine kinase-2 into the phosphorylated forms which serve as sphingosine-1-phosphate receptor agonists. The vascular endothelial sphingosine-1-phosphate receptor agonists are employed in methods of treating a mammal for vascular permeability disorders and unwa…
- Who is the assignee on this patent?
- Hla Timothy, Sanchez Teresa, Claffey Kevin Patrick, and 2 more
- What technology area does this patent fall under?
- Primary CPC classification A61K31/661. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Aug 11 2015 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).